Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 06, 2014 16:00 ET | Source: Mateon Therapeutics

OXiGENE Reports First Quarter 2014 Financial Results

Company Strengthens Cash Position by $20 Million Announced Positive Phase 2 Data in Recurrent Ovarian Cancer for ZYBRESTAT® in Combination With Avastin® SOUTH SAN FRANCISCO, Calif.,...
April 22, 2014 16:30 ET | Source: Mateon Therapeutics

OXiGENE Announces First Quarter 2014 Earnings Conference Call and Webcast

SOUTH SAN FRANCISCO, Calif., April 22, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, will report first...
April 07, 2014 09:00 ET | Source: Mateon Therapeutics

OXiGENE Announces Results of Promising Preclinical Studies at 2014 AACR Conference

SOUTH SAN FRANCISCO, Calif., April 7, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, today announced...
March 27, 2014 08:30 ET | Source: Mateon Therapeutics

OXiGENE Announces Presentation of Three Preclinical Abstracts at 2014 AACR Conference

SOUTH SAN FRANCISCO, Calif., March 27, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, today announced...
March 18, 2014 16:00 ET | Source: Mateon Therapeutics

OXiGENE Reports Full Year 2013 Financial Results

SOUTH SAN FRANCISCO, Calif., March 18, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, reported...
March 11, 2014 17:42 ET | Source: Mateon Therapeutics

UPDATE -- OXiGENE Announces Positive Topline Results From Randomized Phase 2 Study GOG186I of ZYBRESTAT(R) in Combination With Avastin(R) for Recurrent Ovarian Cancer

SOUTH SAN FRANCISCO, Calif., March 11, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, today announced...
March 11, 2014 15:35 ET | Source: Mateon Therapeutics

OXiGENE Announces Positive Topline Results From Randomized Phase 2 Study GOG186I of ZYBRESTAT(R) in Combination With Avastin(R) for Recurrent Ovarian Cancer

SOUTH SAN FRANCISCO, Calif., March 11, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, today announced...
March 11, 2014 13:03 ET | Source: Mateon Therapeutics

OXiGENE Announces Updated Time for Presentation at the ROTH Conference

SOUTH SAN FRANCISCO, Calif., March 11, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that...
March 07, 2014 09:00 ET | Source: Mateon Therapeutics

OXiGENE Announces Presentation at the ROTH Conference on March 11, 2014

SOUTH SAN FRANCISCO, Calif., March 7, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that...
March 04, 2014 06:00 ET | Source: Mateon Therapeutics

OXiGENE Announces Full Year 2013 Earnings Conference Call and Webcast

SOUTH SAN FRANCISCO, Calif., March 4, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, will report...